Freeline Therapeutics Holdings plc (NASDAQ:FRLN) Expected to Post Earnings of -$0.64 Per Share

Brokerages expect Freeline Therapeutics Holdings plc (NASDAQ:FRLNGet Rating) to post earnings per share of ($0.64) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Freeline Therapeutics’ earnings. The highest EPS estimate is ($0.46) and the lowest is ($0.90). Freeline Therapeutics posted earnings per share of ($0.98) during the same quarter last year, which indicates a positive year-over-year growth rate of 34.7%. The company is scheduled to report its next earnings report on Monday, January 1st.

On average, analysts expect that Freeline Therapeutics will report full-year earnings of ($2.26) per share for the current financial year, with EPS estimates ranging from ($3.51) to ($1.47). For the next fiscal year, analysts anticipate that the business will report earnings of ($1.63) per share, with EPS estimates ranging from ($2.99) to ($0.90). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that that provide coverage for Freeline Therapeutics.

Freeline Therapeutics (NASDAQ:FRLNGet Rating) last issued its quarterly earnings results on Thursday, March 31st. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.25).

FRLN has been the subject of several analyst reports. Zacks Investment Research cut shares of Freeline Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, April 4th. Morgan Stanley cut shares of Freeline Therapeutics from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, February 1st. Stifel Nicolaus reissued a “buy” rating on shares of Freeline Therapeutics in a research note on Friday, February 11th. Finally, Redburn Partners upgraded Freeline Therapeutics from a “neutral” rating to a “buy” rating in a research report on Friday, January 7th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $11.21.

Hedge funds have recently modified their holdings of the company. Values First Advisors Inc. acquired a new position in shares of Freeline Therapeutics during the 4th quarter worth approximately $46,000. Prospera Financial Services Inc acquired a new stake in shares of Freeline Therapeutics during the 3rd quarter worth about $51,000. Citadel Advisors LLC bought a new stake in shares of Freeline Therapeutics during the 2nd quarter worth about $108,000. Morgan Stanley boosted its holdings in shares of Freeline Therapeutics by 22.9% during the third quarter. Morgan Stanley now owns 41,341 shares of the company’s stock worth $141,000 after acquiring an additional 7,704 shares during the period. Finally, SG Americas Securities LLC acquired a new position in Freeline Therapeutics in the 3rd quarter valued at $163,000. 47.05% of the stock is currently owned by institutional investors.

Shares of FRLN stock opened at $0.90 on Friday. Freeline Therapeutics has a 12 month low of $0.75 and a 12 month high of $15.40. The stock has a 50-day moving average price of $1.03.

About Freeline Therapeutics (Get Rating)

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B.

Featured Articles

Get a free copy of the Zacks research report on Freeline Therapeutics (FRLN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Freeline Therapeutics (NASDAQ:FRLN)

Receive News & Ratings for Freeline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Freeline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.